249 related articles for article (PubMed ID: 21878748)
1. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
Inoue H; Hwang SH; Wecksler AT; Hammock BD; Weiss RH
Cancer Biol Ther; 2011 Nov; 12(9):827-36. PubMed ID: 21878748
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
7. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
Shiota M; Eto M; Yokomizo A; Tada Y; Takeuchi A; Masubuchi D; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
Int J Oncol; 2010 Jun; 36(6):1521-31. PubMed ID: 20428777
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract][Full Text] [Related]
12. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Matsuda Y; Fukumoto M
Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
15. Therapy for metastatic RCC--questions remain.
Breau RH; Leibovich BC
Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
[No Abstract] [Full Text] [Related]
16. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
17. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
19. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
20. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
